MiRNA array of clear cell renal cell carcinoma from patients treated with sunitinib
Ontology highlight
ABSTRACT: A multiple receptor tyrosine kinase inhibitor, sunitinib, is a first-line therapy for clear cell renal cell carcinoma (CCRCC). Unfortunately, it has the major challenges of low initial response rate and resistance after about one year of treatment. Here we evaluated a microRNA (miRNA) and its target responsible for sunitinib resistance. Using miRNA profiling, we identified miR-96-5p upregulation in tumors from sunitinib-resistant CCRCC patients
ORGANISM(S): Homo sapiens
PROVIDER: GSE189331 | GEO | 2021/12/03
REPOSITORIES: GEO
ACCESS DATA